keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer survival

keyword
https://www.readbyqxmd.com/read/29166331/223ra-therapy-in-patients-with-advanced-castration-resistant-prostate-cancer-with-bone-metastases-lessons-from-daily-practice
#1
Maarten J van der Doelen, Malou C P Kuppen, Marianne A Jonker, Niven Mehra, Marcel J R Janssen, Inge M van Oort, Winald R Gerritsen
PURPOSE: To identify pre-therapeutic variables associated with overall survival (OS) in patients treated with Ra. METHODS: Data from 45 CRPC patients treated with Ra were retrospectively analyzed. All patients who received at least one Ra injection were included in the study. Cox proportional hazard regression models were used to estimate hazard ratio's (HR) and to test for association. RESULTS: Twenty-one patients (47%) received six Ra injections and 24 patients (53%) received one to five Ra injections...
November 22, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29166142/effects-of-dose-escalated-radiotherapy-in-combination-with-long-term-androgen-deprivation-on-prostate-cancer
#2
Natsuo Tomita, Norihito Soga, Yuji Ogura, Jun Furusawa, Hidetoshi Shimizu, Sou Adachi, Hiroshi Tanaka, Daiki Kato, Yutaro Koide, Chiyoko Makita, Hiroyuki Tachibana, Takeshi Kodaira
OBJECTIVE: We aimed to examine the effects of a dose escalation for prostate cancer patients receiving long-term androgen deprivation therapy (ADT). METHODS: A retrospective analysis of 605 patients treated with radiotherapy and long-term ADT (National Comprehensive Cancer Network criteria-defined intermediate-risk; minimum 10 months, high-risk and very-high-risk; minimum 20 months) was performed. The median ADT time was 31 months. Cox's proportional-hazards models were used to compare biochemical disease-free survival (bDFS), clinical relapse-free survival (cRFS), and overall survival (OS) between the ≥ 70, < 78 Gy group and 78 Gy group in a univariate analysis and to assess the effects of the dose escalation on bDFS in a multivariate analysis...
November 22, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/29164346/impact-of-prior-androgen-receptor-axis-targeted-agents-on-the-clinical-activity-of-subsequent-docetaxel-in-patients-with-metastatic-castration-resistant-prostate-cancer-comparative-assessment-between-abiraterone-acetate-and-enzalutamide
#3
Hideaki Miyake, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Takayuki Sugiyama, Atsushi Otsuka
The objective of this study was to investigate the impact of prior treatment with androgen receptor-axis-targeted (ARAT) agents, abiraterone acetate (AA) and enzalutamide (Enz), on the activity of subsequently introduced docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). This study included a total of 114 mCRPC patients consisting of 54 and 60 who progressed following treatment with AA and Enz, respectively, prior to the introduction of docetaxel, and compared oncological outcomes with docetaxel between these two groups...
November 21, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29164326/men-with-family-history-of-prostate-cancer-have-a-higher-risk-of-disease-recurrence-after-radical-prostatectomy
#4
Mark Thalgott, Martina Kron, Johannes M Brath, Donna P Ankerst, Ian M Thompson, Juergen E Gschwend, Kathleen Herkommer
PURPOSE: We aimed to determine if family history (FH) of prostate cancer (PC) influenced cancer control after radical prostatectomy (RP). METHODS: Patients were evaluated in a prospectively-collected PC family database: The focus was on hereditary prostate cancer (HPC) defined by Johns Hopkins criteria and sporadic prostate cancer (SPC), rigorously defined by absence of prostate cancer in ≥ 2 brothers aged ≥ 60 years. Additionally, patients with first-degree (FPC) and non-first-degree PC (non-FPC) were assessed...
November 21, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/29164270/long-term-outcomes-in-patients-younger-than-60%C3%A2-years-of-age-treated-with-brachytherapy-for-prostate-cancer
#5
Pedro J Prada, Juan Cardenal, Ana García Blanco, Javier Anchuelo, María Ferri, Ivan Diaz de Cerio, Andrés Vázquez, Maite Pacheco, Samuel Ruiz Arrebola
PURPOSE: The purpose of the study was to report the outcomes and late toxicities in patients younger than 60 years of age with long-term follow-up treated with low dose rate (LDR) brachytherapy for localized prostate cancer. METHODS: Between January 2000 and December 2009, 270 consecutive patients were treated with favourable localized prostate cancer; the median follow-up was 111 months (range 21-206). All patients received one implant of LDR brachytherapy. Toxicity was reported according to the Common Toxicity Criteria for Adverse Events, Version 4...
November 21, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29163775/loss-of-sun2-promotes-the-progression-of-prostate-cancer-by-regulating-fatty-acid-oxidation
#6
Cheng Yajun, Ye Chen, Li Xiaosa, Wang Xiao, Chen Jia, Wang Zhong, Xu Bin
The role of Sun2 has been described by previous studies in various types of cancers, including breast cancer and lung cancer. However, its role and potential molecular mechanism in the progression of prostate cancer have not been fully elucidated. In the present study, we found that Sun2 expression was reduced in prostate cancer tissues compared with paired normal tissues, and that low expression of Sun2 was significantly correlated with Higher Gleason scores, postoperative T stage (pT), Lymph nodal invasion and Clinical pathological stages...
October 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/29163712/combinations-of-elevated-tissue-mirna-17-92-cluster-expression-and-serum-prostate-specific-antigen-as-potential-diagnostic-biomarkers-for-prostate-cancer
#7
Sujuan Feng, Xiaosong Qian, Han Li, Xiaodong Zhang
The aim of the present study was to investigate the effectiveness of the miR-17-92 cluster as a disease progression marker in prostate cancer (PCa). Reverse transcription-quantitative polymerase chain reaction analysis was used to detect the microRNA (miR)-17-92 cluster expression levels in tissues from patients with PCa or benign prostatic hyperplasia (BPH), in addition to in PCa and BPH cell lines. Spearman correlation was used for comparison and estimation of correlations between miRNA expression levels and clinicopathological characteristics such as the Gleason score and prostate-specific antigen (PSA)...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29163701/high-levels-of-depdc1b-predict-shorter-biochemical-recurrence-free-survival-of-patients-with-prostate-cancer
#8
Shoumin Bai, Ting Chen, Tao Du, Xianju Chen, Yiming Lai, Xiaoming Ma, Wanhua Wu, Chunhao Lin, Leyuan Liu, Hai Huang
DEP domain-containing protein 1B (DEPDC1B) has been reported to serve important functions in breast cancer and non-small cell lung cancer. However, its involvement in the development of prostate cancer (PCa) remains unclear. Therefore, the present study aimed to investigate the expression and clinical significance of DEPDC1B in tumor tissues from patients diagnosed with PCa. A total of 80 prostate tissue samples were collected following prostatectomy to generate a tissue microarray for immunohistochemical analysis of DEPDC1B protein expression...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29161715/management-of-biochemical-recurrence-after-primary-curative-treatment-for-prostate-cancer-a-review
#9
Walter Artibani, Antonio Benito Porcaro, Vincenzo De Marco, Maria A Cerruto, Salvatore Siracusano
How to manage patients with prostate cancer (PCa) with biochemical recurrence (BCR) following primary curative treatment is a controversial issue. Importantly, this prostate-specific antigen (PSA)-only recurrence is a surrogate neither of PCa-specific survival nor of overall survival. Physicians are therefore challenged with preventing or delaying the onset of clinical progression in those deemed at risk, while avoiding over-treating patients whose disease may never progress beyond PSA-only recurrence. Adjuvant therapy for radical prostatectomy (RP) or local radiotherapy (RT) has a role in certain at-risk patients, although it is not recommended in low-risk PCa owing to the significant side-effects associated with RT and androgen deprivation therapy (ADT)...
November 21, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/29160310/cyclin-d-cdk4-kinase-destabilizes-pd-l1-via-cul3-spop-to-control-cancer-immune-surveillance
#10
Jinfang Zhang, Xia Bu, Haizhen Wang, Yasheng Zhu, Yan Geng, Naoe Taira Nihira, Yuyong Tan, Yanpeng Ci, Fei Wu, Xiangpeng Dai, Jianping Guo, Yu-Han Huang, Caoqi Fan, Shancheng Ren, Yinghao Sun, Gordon J Freeman, Piotr Sicinski, Wenyi Wei
Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit(1,2). However, many cancer patients fail to respond to anti-PD-1/PD-L1 treatment, and the underlying mechanism(s) is not well understood(3-5). Recent studies revealed that response to PD-1/PD-L1 blockade might correlate with PD-L1 expression levels in tumor cells(6,7). Hence, it is important to mechanistically understand the pathways controlling PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1/PD-L1 blockade in cancer patients...
November 16, 2017: Nature
https://www.readbyqxmd.com/read/29159872/the-dark-side-of-glucose-transporters-in-prostate-cancer-are-they-a-new-feature-to-characterize-carcinomas
#11
REVIEW
Pedro Gonzalez-Menendez, David Hevia, Juan C Mayo, Rosa M Sainz
One of the hallmarks of cancer cells is the increased ability to acquire nutrients, particularly glucose and glutamine. Proliferating cells need precursors for cell growth and NADPH reducing equivalents for survival. The principal responsible for glucose uptake is facilitative glucose transporters (GLUTs), which usually are overexpressed in cancer cells. Besides their role in glucose uptake, GLUT transporters are able to transport other compounds such as dehydroascorbic acid or uric acid. They play a major role in tumor progression and cellular processes such as regulated cell death...
November 21, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29158807/the-prognostic-value-of-peripheral-benzodiazepine-receptor-in-patients-with-esophageal-squamous-cell-carcinoma
#12
You-Fang Chen, Jing-Dun Xie, Yu-Chuan Jiang, Dong-Tai Chen, Jia-Hao Pan, Yong-Hua Chen, Yun-Fei Yuan, Zhe-Sheng Wen, Wei-An Zeng
Background: The peripheral benzodiazepine receptor (PBR) has previously been reported as an oncogene in prostate, breast and colorectal cancers, but its prognostic value, biological behavior and function in esophageal squamous cell carcinoma (ESCC) has not been investigated. Methods: qRT-PCR, western blotting and immunohistochemistry (IHC) were used to detect PBR expression in ESCC and matched non-cancerous tissues. Based on all of the significantly independent factors, a nomogram was established to predict the prognosis of ESCC patients...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29158269/the-glucocorticoid-receptor-is-a-key-player-for-prostate-cancer-cell-survival-and-a-target-for-improved-anti-androgen-therapy
#13
Martin Puhr, Julia Hoefer, Andrea Eigentler, Christian Ploner, Florian Handle, Georg Schaefer, Jan Kroon, Angela Leo, Isabel M Heidegger, Iris E Eder, Zoran Culig, Gabri van der Pluijm, Helmut Klocker
PURPOSE: The major obstacle in the management of advanced prostate cancer (PCa) is the occurrence of resistance to endocrine-therapy. Although the androgen receptor (AR) has been linked to therapy failure, the underlying escape mechanisms have not been fully clarified. Being closely related to the AR, the glucocorticoid receptor (GR) has been suggested to play a role in enzalutamide and docetaxel resistance. Given that glucocorticoids are frequently applied to PCa patients, it is essential to unravel the exact role of the GR in PCa progression...
November 20, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29158136/it-s-all-about-the-perspective-removing-bias-when-co-managing-patients-with-high-grade-t1-bladder-cancer-and-localized-prostate-cancer-a-competing-risks-analysis
#14
J E Ferguson, Ashish M Kamat
The risk connotation of terminology in influencing decision-making should not be underestimated. For example, "superficial" T1HG bladder cancer has the same poor cancer-specific survival as that conferred by the "highest risk" prostate cancer (Gleason 10, T3b). Co-management of concomitant prostate cancer and non-muscle invasive bladder cancer requires a careful competing risk analysis by both the physician and patient. Herein, we detail how patients and physicians should be careful not to underestimate the risk attributed to "non-muscle invasive" bladder cancer...
November 17, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29156895/survival-analysis-of-malignant-epidural-spinal-cord-compression-after-palliative-radiotherapy-using-tokuhashi-scoring-system-and-the-impact-of-systemic-therapy
#15
Wing Ho Mui, Tai Chung Lam, Frank Chi Sing Wong, Wing King Sze
BACKGROUND: Previous studies have shown similar clinical outcomes of both single and multi-fraction (Fr) radiation therapy among malignant epidural spinal cord compression (MSCC) patients with poor prognosis; whereas, patients expected to have longer survival may require long-course radiotherapy to prevent local failure. However, such a poor prognosis risk group has not yet been clearly identified for use in daily clinical practice. We examined if the known predictive Tokuhashi scoring system could be adapted in MSCC patients treated with palliative radiation therapy...
August 29, 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29156299/outcomes-from-ovarian-cancer-screening-in-the-plco-trial-histologic-heterogeneity-impacts-detection-overdiagnosis-and-survival
#16
Sarah M Temkin, Eric A Miller, Goli Samimi, Christine D Berg, Paul Pinsky, Lori Minasian
AIM: A mortality benefit from screening for ovarian cancer has never been demonstrated. The aim of this study was to evaluate the screening outcomes for different histologic subtypes of ovarian cancers. METHODS: Women in the screening arm of the Prostate, Lung, Colorectal and Ovarian Screening Trial underwent CA-125 and transvaginal ultrasound annually for 3-5 years. We compared screening test characteristics (including overdiagnosis) and outcomes by tumour type (type II versus other) and study arm (screening versus usual care)...
November 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29156009/discovering-cancer-vulnerabilities-using-high-throughput-micro-rna-screening
#17
Iva Nikolic, Benjamin Elsworth, Eoin Dodson, Sunny Z Wu, Cathryn M Gould, Pieter Mestdagh, Glenn M Marshall, Lisa G Horvath, Kaylene J Simpson, Alexander Swarbrick
Micro-RNAs (miRNAs) are potent regulators of gene expression and cellular phenotype. Each miRNA has the potential to target hundreds of transcripts within the cell thus controlling fundamental cellular processes such as survival and proliferation. Here, we exploit this important feature of miRNA networks to discover vulnerabilities in cancer phenotype, and map miRNA-target relationships across different cancer types. More specifically, we report the results of a functional genomics screen of 1280 miRNA mimics and inhibitors in eight cancer cell lines, and its presentation in a sophisticated interactive data portal...
November 16, 2017: Nucleic Acids Research
https://www.readbyqxmd.com/read/29154022/the-anti-tumor-effect-of-rankl-inhibition-in-malignant-solid-tumors-a-systematic-review
#18
REVIEW
A F de Groot, N M Appelman-Dijkstra, S H van der Burg, J R Kroep
At present, accumulating evidence suggests that inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) does not only induce an increase in bone mass and strength, but also has anti-tumor effects. Denosumab, an antibody targeting RANKL, is used to treat osteoporosis and to prevent skeletal related events (SREs) in patients with bone metastases originating from solid tumors. However, expression of RANKL and its receptor activator of nuclear factor kappa-B (RANK) is not solely restricted to cells involved in homeostasis of the bone and RANKL-RANK signalling appears to play a substantial role in many other processes in the body like mammary physiology, mammary tumorigenesis and the immune system...
November 2, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29153623/abiraterone-acetate-prednisolone-treatment-beyond-prostate-specific-antigen-and-radiographic-progression-in-metastatic-castration-resistant-prostate-cancer-patients
#19
Krisztina Biró, Barna Budai, Márta Szőnyi, Zsófia Küronya, Fruzsina Gyergyay, Krisztián Nagyiványi, Lajos Géczi
OBJECTIVES: To investigate the overall survival (OS) of chemotherapy refractory patients with metastatic castration-resistant prostate cancer who were treated with abiraterone acetate + prednisolone (AA + P) beyond prostate specific antigen (PSA) and radiographic progression (PRP) until clinical progression in comparison to patients treated until PRP. METHODS: At our institute the AA + P treatment started in 2011 in an early-access protocol trial. In October 2012 AA became generally available...
November 15, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29152681/trichothecenes-immunomodulatory-effects-mechanisms-and-anti-cancer-potential
#20
REVIEW
Qinghua Wu, Xu Wang, Eugenie Nepovimova, Anca Miron, Qianying Liu, Yun Wang, Dongxiao Su, Hualin Yang, Li Li, Kamil Kuca
Paradoxically, trichothecenes have both immunosuppressive and immunostimulatory effects. The underlying mechanisms have not been fully explored. Early studies show that dose, exposure timing, and the time at which immune function is assessed influence whether trichothecenes act in an immunosuppressive or immunostimulatory fashion. Recent studies suggest that the immunomodulatory function of trichothecenes is also actively shaped by competing cell-survival and death-signaling pathways. Autophagy may also promote trichothecene immunosuppression, although the mechanism may be complicated...
November 20, 2017: Archives of Toxicology
keyword
keyword
8536
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"